Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2021; 43(03): 185-189
DOI: 10.1055/s-0040-1719149
Original Article
Mastology

Switching of Hormone Therapies in Breast Cancer Women

Avaliação da mudança do esquema hormonioterápico em mulheres com câncer de mama
Luana Moreira de Medeiros 
1   Faculty of Pharmaceutical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
,
Rebeca Stahlschmidt 
2   Graduate Program in Medical Sciences, Faculty of Medical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
,
Amanda Canato Ferracini 
2   Graduate Program in Medical Sciences, Faculty of Medical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
,
Cinthia Madeira de Souza 
2   Graduate Program in Medical Sciences, Faculty of Medical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
,
Cassia Raquel Teatin Juliato 
3   Department of Obstetrics and Gynecology, Faculty of Medical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
,
Priscila Gava Mazzola 
1   Faculty of Pharmaceutical Sciences, Universidade de Campinas (Unicamp), Campinas, SP, Brazil
› Author Affiliations
› Further Information
   Permissions and Reprints

Abstract

Objective The objective of the present study was to analyze the reasons that led to hormone therapies (HTs) regimen changes in women with breast cancer.

Methods This was a retrospective cross-sectional study from a single-institution Brazilian cancer center with patient records diagnosed with breast cancer between January 2012 and January 2017.

Results From 1,555 women who were in treatment with HT, 213 (13.7%) women had HT switched, either tamoxifen to anastrozole or vice-versa. Most women included in the present study who switched HT were > 50 years old, postmenopausal, Caucasian, and had at least one comorbidity. From the group with therapy change, ‘disease progression’ was reason of change in 124 (58.2%) cases, and in 65 (30.5%) patients, ‘presence of side effects’ was the reason. From those women who suffered with side effects, 24 (36.9%) had comorbidities.

Conclusion The present study demonstrated a low rate of HT switch of tamoxifen to anastrozole. Among the reasons for changing therapy, the most common was disease progression, which includes cancer recurrence, metastasis or increased tumor. Side effects were second; furthermore, age and comorbidities are risk factors for side effects.

Resumo

Objetivo O objetivo do presente estudo foi analisar os motivos que levaram às mudanças no esquema hormonioterápico (HT) em mulheres com câncer de mama.

Métodos Estudo transversal retrospectivo realizado no Hospital da Mulher de Campinas e consequente pesquisa de prontuários de mulheres diagnosticados com câncer de mama entre janeiro de 2012 e janeiro de 2017.

Resultados De 1.555 mulheres em tratamento com HT, 213 (13,7%) mulheres tiveram HT alterado, tamoxifeno para anastrozol ou vice-versa. A maioria das mulheres incluídas no presente estudo que tiveram mudança de HT tinha > 50 anos, estava na pós-menopausa, era caucasiana e tinha pelo menos uma comorbidade. Os principais motivos de troca de HT foram devido a 'progressão da doença', ocorrendo em 124 (58,2%) casos e a 'presença de efeitos colaterais' (n = 65; 30,5%). Das mulheres que sofreram efeitos colaterais, 24 (36,9%) apresentaram comorbidades.

Conclusão O presente estudo demonstrou uma baixa taxa na alteração de tamoxifeno para anastrozol. Entre as razões mais comuns para alterar a HT estava a progressão da doença, que inclui recorrência do câncer, metástase ou aumento do tumor. Os efeitos colaterais foram a segunda causa e, além disso, a idade e as comorbidades foram fatores de risco para efeitos colaterais.

Keywords

breast cancer - tamoxifen - hormone therapy - aromatase inhibitor - anastrozole

Palavras-chave

câncer de mama - tamoxifeno - terapia hormonal - inibidor da aromatase - anastrozol

Contributors

All of the authors contributed with the project and data interpretation, the writing of the article, the critical review of the intellectual content, and with the final approval of the version to be published.




Publication History

Received: 04 July 2020

Accepted: 21 September 2020

Article published online:
19 January 2021

© 2021. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil

 

  • References

  • 1 World Health Organization. Cancer: diagnosis and treatment [Internet]. 2017 [cited 2020 Apr 15]. Available from: https://www.who.int/cancer/treatment/en/
    Search in Google Scholar
  • 2 World Health Organization. Breast cancer [Internet]. 2018 [cited 2020 Apr 15]. Available from: https://www.who.int/cancer/prevention/diagnosis-screening/breast-cancer/en/
    Search in Google Scholar
  • 3 Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 2019; 37 (05) 423-438
    CrossrefPubMedSearch in Google Scholar
  • 4 Güth U, Myrick ME, Schötzau A, Kilic N, Schmid SM. Drug switch because of treatment-related adverse side effects in endocrine adjuvant breast cancer therapy: how often and how often does it work?. Breast Cancer Res Treat 2011; 129 (03) 799-807
    CrossrefPubMedSearch in Google Scholar
  • 5 Kwan ML, Roh JM, Laurent CA, Lee J, Tang L, Hershman D. et al. Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control 2017; 28 (06) 557-562
    CrossrefPubMedSearch in Google Scholar
  • 6 Moscetti L, Agnese Fabbri M, Sperduti I, Fabrizio N, Frittelli P, Massari A. et al. Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?. Tumori 2015; 101 (05) 469-473
    CrossrefPubMedSearch in Google Scholar
  • 7 Khandelwal N, Duncan I, Ahmed T, Rubinstein E, Pegus C. Oral chemotherapy program improves adherence and reduces medication wastage and hospital admissions. J Natl Compr Canc Netw 2012; 10 (05) 618-625
    CrossrefPubMedSearch in Google Scholar
  • 8 Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NA, Gelmon KE. et al. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 2014; 32 (21) 2255-2269
    CrossrefPubMedSearch in Google Scholar
  • 9 Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45 (02) 228-247
    CrossrefPubMedSearch in Google Scholar
  • 10 National Institutes of Health, National Cancer Institute, U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) v4.0 [Internet]. 2009 [cited 2020 Apr 22]. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
    Search in Google Scholar
  • 11 Tinari N, Fanizza C, Romero M, Gambale E, Moscetti L, Vaccaro A. et al. Identification of subgroups of early breast cancer patients at high risk of nonadherence to adjuvant hormone therapy: results of an Italian survey. Clin Breast Cancer 2015; 15 (02) e131-e137
    CrossrefPubMedSearch in Google Scholar
  • 12 Witsch E, Sela M, Yarden Y. Roles for growth factors in cancer progression. Physiology (Bethesda) 2010; 25 (02) 85-101
    CrossrefPubMedSearch in Google Scholar
  • 13 Salkeni MA, Hall SJ. Metastatic breast cancer: Endocrine therapy landscape reshaped. Avicenna J Med 2017; 7 (04) 144-152
    Thieme ConnectPubMedSearch in Google Scholar
  • 14 Masur K, Vetter C, Hinz A, Thomas N, Henrich H, Niggemann B, Zänker KS. Diabetogenic glucose and insulin concentrations modulate transcriptome and protein levels involved in tumour cell migration, adhesion and proliferation. Br J Cancer 2011; 104 (02) 345-352
    CrossrefPubMedSearch in Google Scholar
  • 15 Ho CH, Chen YC, Wang JJ, Liao KM. Incidence and relative risk for developing cancer among patients with COPD: a nationwide cohort study in Taiwan. BMJ Open 2017; 7 (03) e013195
    CrossrefPubMedSearch in Google Scholar
  • 16 Nelson ER, Chang CY, McDonnell DP. Cholesterol and breast cancer pathophysiology. Trends Endocrinol Metab 2014; 25 (12) 649-655
    CrossrefPubMedSearch in Google Scholar
  • 17 Noguchi S, Ellis MJ, Robertson JFR, Thirlwell J, Fazal M, Shao Z. Progression-free survival results in postmenopausal Asian women: subgroup analysis from a phase III randomized trial of fulvestrant 500 mg vs anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON). Breast Cancer 2018; 25 (03) 356-364
    CrossrefPubMedSearch in Google Scholar
  • 18 Reinert T, Barrios CH. Overall survival and progression-free survival with endocrine therapy for hormone receptor-positive, HER2-negative advanced breast cancer: review. Ther Adv Med Oncol 2017; 9 (11) 693-709
    CrossrefPubMedSearch in Google Scholar
  • 19 Stahlschmidt R, Ferracini AC, de Souza CM, de Medeiros LM, Juliato CRT, Mazzola PG. Adherence and quality of life in women with breast cancer being treated with oral hormone therapy. Support Care Cancer 2019; 27 (10) 3799-3804
    CrossrefPubMedSearch in Google Scholar
  • 20 Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007; 370 (9587): 591-603
    CrossrefPubMedSearch in Google Scholar
  • 21 Anderson TJ, Grégoire J, Pearson GJ, Barry AR, Couture P, Dawes M. et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2016; 32 (11) 1263-1282
    CrossrefPubMedSearch in Google Scholar
  • 22 Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res 2004; 59: 31-50
    CrossrefPubMedSearch in Google Scholar
  • 23 Stratton IM, Adler AI, Neil HAW, Matthews DR, Manley SE, Cull CA. et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321 (7258): 405-412
    CrossrefPubMedSearch in Google Scholar
  • 24 Sayin N, Kara N, Pekel G. Ocular complications of diabetes mellitus. World J Diabetes 2015; 6 (01) 92-108
    CrossrefPubMedSearch in Google Scholar
  • 25 Kim JH, Park HS, Ko SY, Hong SN, Sung I-K, Shim CS. et al. Diabetic factors associated with gastrointestinal symptoms in patients with type 2 diabetes. World J Gastroenterol 2010; 16 (14) 1782-1787
    CrossrefPubMedSearch in Google Scholar
  • 26 Richard J, Lingvay I. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther 2011; 9 (03) 321-328
    CrossrefPubMedSearch in Google Scholar
  • 27 Freiman A, Bird G, Metelitsa AI, Barankin B, Lauzon GJ. Cutaneous effects of smoking. J Cutan Med Surg 2004; 8 (06) 415-423
    CrossrefPubMedSearch in Google Scholar
  • 28 El-Zayadi AR. Heavy smoking and liver. World J Gastroenterol 2006; 12 (38) 6098-6101
    CrossrefPubMedSearch in Google Scholar
  • 29 American College of Obstetricians and Gynecologists (ACOG). Endometrial hyperplasia [Internet]. 2020 [cited 2020 Apr 15]. Available from: https://www.acog.org/Patients/FAQs/Endometrial-Hyperplasia#causes
    Search in Google Scholar
  • 30 McBane SE, Dopp AL, Abe A, Benavides S, Chester EA, Dixon DL. American College of Clinical Pharmacy. , et al; Collaborative drug therapy management and comprehensive medication management-2015. Pharmacotherapy 2015; 35 (04) e39-e50
    CrossrefPubMedSearch in Google Scholar
  • 31 Jackson K, Letton C, Maldonado A, Bodiford A, Sion A, Hartwell R. et al. A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics. J Oncol Pharm Pract 2019; 25 (04) 847-854
    CrossrefPubMedSearch in Google Scholar